Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of California, San Francisco |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00596232 |
The purpose of this study is to investigate how mucus (phlegm or spit) is broken down once it forms in the airways (bronchial tubes) of people with lung disease. This research study will also examine whether blood groups have an effect on lung function or the type of mucus found in the lung. This study is not designed to be a treatment for asthma, emphysema, cystic fibrosis, or other lung disease. It is designed to help the investigators learn more about the causes of airway disease.
Condition |
---|
Asthma Cystic Fibrosis Smokers |
Study Type: | Observational |
Study Design: | Case Control, Cross-Sectional |
Official Title: | Investigating Mucinase Activity in Airway Disease |
Sputum
Estimated Enrollment: | 225 |
Study Start Date: | April 2003 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Asthma
People who have been diagnosed with Asthma
|
CF
People who have been diagnosed with Cystic Fibrosis
|
Smokers
People who either have a history of cigarette smoking of at least 10 pack years and current smoking of at least 10 cigarettes a day, or have a history of cigarette smoking of at least 10 pack years and FEV1/FVC ratio less than 0.7.
|
Healthy
People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
|
Accumulation of mucus in the airway involves the process of overproduction and reduced clearance of mucin glycoproteins. To date, little attention has been focused on mechanisms of mucin clearance from the airway. We hypothesize that there is enzymatic degradation of mucins ("mucinase activity") in the airway, which acts to break down mucins and facilitate their clearance. We further hypothesize that glycosidases function as mucinases by removing peripheral monosaccharides from oligosaccharides, including oligosaccharides on mucins.
Removal of terminal or capping sugars on mucin side chains may be an important mechanism in mucin degradation and clearance from the lung. If mucinase activity exists in the airway then mucus collected from human subjects should demonstrate evidence of mucin degradation ex vivo, especially at 37ºC. As part of our protocol we propose to examine changes in airway mucus ex vivo under different experimental conditions. Our primary readout will be measures of sputum rheology, namely viscosity and elasticity. Our consultant for this methodology will be Dr Susan Muller (Chemical Engineering, UC Berkeley). In order to conduct experimental studies in this way we will need multiple samples from the same subjects. Thus, up to 10 or more sputum samples per subject will be collected on different days. In addition, we are interested in the biochemical properties of sputum and saliva, specifically the composition of mucin molecules found in these fluids.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Volunteers are recruited from community advertisements and health clinics
Inclusion Criteria:
Asthma:
Smokers:
Cystic Fibrosis:
Healthy:
Exclusion Criteria:
Contact: Kimberly S Okamoto, BS | 415-514-1539 | kimberly.okamoto@ucsf.edu |
Contact: Rachel Harold, BA | 415-476-5040 | rachel.harold@ucsf.edu |
United States, California | |
UCSF Airway Clinical Research Center | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Kimberly S Okamoto, BS 415-514-1539 kimberly.okamoto@ucsf.edu |
Principal Investigator: | John V Fahy, M.D., M.Sc. | University of California, San Francisco |
Responsible Party: | University of California, San Francisco ( John V. Fahy, M.D., M.Sc. ) |
Study ID Numbers: | UCSF CHR# H6788-22648-05 |
Study First Received: | January 2, 2008 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00596232 History of Changes |
Health Authority: | United States: Institutional Review Board |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis Fibrosis |
Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases Asthma |
Pathologic Processes Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases |